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ReseaRch On MOdeling MethOds studies
MO1
a unified fRaMewORk fOR classificatiOn Of MethOds fOR Benefit-Risk 
assessMent
Najafzadeh M.1, Schneeweiss S.1, Choudhry N.K.1, Bykov K.1, Kahler K.2, Martin D.2,  
Arcona S.2, Rogers J.R.1, Gagne J.J.1
1Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, 2Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA
Objectives: Patients, physicians, and other decision-makers make implicit trade-
offs among benefits and risks of different treatments. Many methods have been 
proposed to conduct quantitative benefit-risk analysis (BRA). We propose a frame-
work for classifying BRA methods based on factors that matter most to patients. 
Using common mathematical notation, we compare the methods using a hypo-
thetical example. MethOds: We classified available BRA methods into three cat-
egories: (1) un-weighted metrics, that use only probabilities of benefits and risks 
(e.g., number needed to treat and number needed to harm [NNT|NNH]); (2) metrics 
that incorporate preference weights to account for the impact and duration of out-
comes (e.g., Maximum Acceptable Risk [MAR], relative value-adjusted life-years 
[RVALYs], quality-adjusted life-years [QALYs]); and (3) metrics that incorporate 
ad hocweights based on decision makers’ opinions (e.g., Multi-criteria Decision 
Analysis, Benefit-Less-Risk Analysis). We used two hypothetical antiplatelet drugs 
(A and B), probabilities of benefits (reduction in myocardial infarction and stroke) 
and harms (increases in major and minor bleeding) based on randomized trial data, 
and preference weights from the literature to compare the BRA methods within 
the proposed framework. Results: Use of the framework and notation revealed 
BRA methods share substantial commonality. In the example, BRA using NNT|NNH 
indicated that -1.3% of patients would experience net benefit with drug A versus 
B, (an unfavorable benefit-risk balance for A). In contrast, 4.6% of patients would 
experience a net benefit with drug A if weighted using MAR. BRA using RVALYs and 
QALYs suggested gains of 3.8 RVALYs and 5.4 QALYs per 100 patient-years, respec-
tively, with drug A versus B. cOnclusiOns: The proposed framework provides 
a unified, patient-centered approach to BRA methods classification. All methods 
impose trade-offs between probabilities of benefits and risks. The weights used 
in the metrics is a key differentiating feature and can lead to quantitatively and 
qualitatively different results.
MO2
Benefits fROM incORpORating netwORk Meta-analysis within 
stRatified cOst-effectiveness analysis
Coyle D.1, Coyle K.2, Cameron C.1, Lee K.M.3, Kelly S.1, Steiner S.4, Wells G.5
1University of Ottawa, Ottawa, ON, Canada, 2Brunel University, Uxbridge, ON, Canada, 
3Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada, 4Medical 
University Vienna, Vienna, Austria, 5University of Ottawa Heart Institute, Ottawa, ON, Canada
Objectives: Network meta-analysis (NMA) is being increasingly used in the eco-
nomic evaluation of medical interventions. One potential advantage of NMA is that 
through stratified analysis it can allow comparison of treatments even when trial 
populations are not homogenous. Such analyses can then facilitate stratified cost 
effectiveness analysis (CEA). This is illustrated through the example of antithrom-
botic treatments for atrial fibrillation (AF) with stratification based on a clinical 
prediction rule (CHADS2). MethOds: Clinical trials in patients with non-valvular 
AF requiring anticoagulation were identified. A Bayesian mixed treatment compari-
son NMA was conducted for stroke, mortality, major bleeding, intracranial hemor-
rhage and myocardial infarction. Where available clinical trial data was obtained 
by CHADS2 score and analysis conducted within three sub groups (CHADS2 score 
< 2, = 2, > 2). Data for warfarin, apixaban, dabigatran 110mg and 150mg (twice daily), 
rivaroxaban, low and medium dose ASA, and clopidogrel plus ASA were available. 
A CEA stratified by CHADS2 score was conducted using a previously published eco-
nomic model. Results: For patients with a CHADS2 score < 2 and = 2, the incre-
mental cost utility ratio, ICUR for dabigatran 150mg versus warfarin was $20,845 
and $23,688 respectively: in both scenarios dabigatran 150mg dominated all other 
alternatives. For patients with a CHADS2 score > 2, the ICUR for apixaban versus 
warfarin was $2,402: apixaban dominated all other alternatives. cOnclusiOns: 
Based on current Canadian thresholds for cost effectiveness, dabigatran 150 mg 
bid was optimal for patients with a CHADS2 score < 2 and = 2, whilst apixaban was 
optimal for patients with a CHADS2 score > 2. This study highlights how NMA can 
be combined with stratified CEA to facilitate meaningful policy recommendations.
MO3
pOpulatiOn health MOdel: pROjecting health tRajectORy Of the 
Massachusetts pOpulatiOn
Olchanski N.1, Zhong Y.1, Winn A.2, Saret C.J.1, Cohen J.T.1
1Tufts Medical Center, Boston, MA, USA, 2University of North Carolina at Chapel Hill, Chapel Hill, 
NC, USA
Objectives: Recent legislation in Massachusetts promotes population health 
improvement while creating incentives to control health care costs. This research 
creates a tool that projects population health in order to predict health care use and 
spending, and to help policy makers make decisions about the allocation of health 
care resources. MethOds:  The Population Health Model is a micro-simulation that 
projects the health status and health care costs for Massachusetts residents over 
50. Drawing from the 1992-2010 Health and Retirement Study, we created modules 
for cancer, heart disease, COPD, diabetes, hypertension, stroke, and mortality risk 
using non-parametric survival analysis which adjusted for demographics, insurance 
status, smoking history, weight, and concurrent diseases. The model simulated indi-
vidual health trajectories over 5 years based on the 2011 state subset of Behavioral 
Risk Factor Surveillance System data. Results:  The model projected that for the 
Massachusetts 2011 cohort, starting disease prevalence rates were 13.5% for diabe-
tes, 42.9% for hypertension, 9.3% for heart disease, 10.6% for cancer, 8.2% for COPD, 
and 3.6% for stroke. Over 5 years, projected incidence rates for this population were 
Medtronic Corevalve (MC)) versus conventional surgery using data from “real-life” 
patients. MethOds: Prospective recruitment in 7 Spanish hospitals, with follow-
up at one, three and six months after intervention. We measured utility with EQ5D. 
We estimated crude and adjusted differences in costs and QALYs using regression 
analyses with bootstrap estimation of variance. We calculated incremental cost-
utility ratios (ICER) comparing ES and MC to AVR and derived cost-effectiveness 
acceptability curves. Subgroup and sensitivity analyses were performed. Results: 
Data from 48 ES-TAVI, 86 MC-TAVI and 52 AVR patients were analyzed; 4 were lost 
to follow up. Mean STS risk score was: ES: 4.9 (3), MC: 5.1 (3), AVR: 5.1 (2). Overall 
cost of ES-TAVI was 7,202 € higher than AVR (adjusted difference: 5,474; 95%CI: 926-
11,875) and the difference in QALYs was 0.045 (adjusted difference: 0.041; 95%CI: 
-0.015 – 0.96), resulting in an ICER of 161,086 € /QALY. The cost of MC-TAVI was 7,476 
€ higher than AVR (adjusted difference: 8,738; 95%CI: 4,480 – 12,997) and the differ-
ence in QALYs was 0.003 (adjusted difference: 0.025; 95%CI: -0.027 – 0.77), resulting 
in an ICER of 2,451,568 € /QALY. The results were mainly driven by the high cost of 
the TAVI device and did not substantially change in the sensitivity analysis and 
subgroups. cOnclusiOns: In the Spanish setting, the use of transfemoral TAVI 
when surgery is feasible is not likely to be cost-effective at a willingness-to-pay 
threshold of 30,000 € /QALY.
Md3
assessing whetheR “Big data” sOlutiOns pROvide value fOR 
diagnOstics ManufactuReRs
Hertz D., Gavaghan M., Garfield S.
GfK Market Access, Wayland, MA, USA
Objectives: Big data has the potential to provide tremendous value to health care 
manufacturers, improving their understanding of unmet clinical need and inform-
ing product development. The objective of this study was to analyze leading payer 
claims databases and EMR systems for diagnostic specific information and costs 
and to determine where unmet needs and opportunities for future data optimiza-
tion exist. MethOds: Five companies who sell large claims and EMR data sets were 
interviewed to understand costs and data granularity. Additionally, interviews were 
conducted with three diagnostic companies that recently purchased big data sets to 
better understand the opportunities and limitations of the data purchased related to 
diagnostic decision-making and research. Results: Datasets reviewed contained 
little granularity related to diagnostic tests. Specifically, because individual tests 
cannot be determined by CPT code, there was no way to determine the brand of 
test used or whether tests were FDA-approved or laboratory developed. Additionally, 
neither claims databases nor EMR systems capture the diagnostic platform used 
for laboratory analysis. There was variation in the detail contained in the databases 
related to lab results. EMR systems seemed to contain greater detail than claims 
system, but lack standards, making it hard to combine data sets. Diagnostic com-
panies are more likely than other health care manufacturers to be small compa-
nies with limited budgets. The current cost of purchasing data, excluding analysis, 
is estimated to be between $25,000 and $200,000. cOnclusiOns: Despite their 
potential, claims and EMR data sources have significant limitations in the detail 
they can provide related to diagnostic and lab services. Additionally, big data is not 
affordabile for many diagnostic companies. As a result, diagnostic companies face 
challenges in demonstrating both shortcomings of existing approaches and the 
clinical and cost utility of novel tests. As diagnostics become more central to health 
decision-making and personalized medicine, data sources need to address existing 
limitations to better demonstrate their clinical and economic impact.
Md4
Real-wORld cOst effectiveness Of the MitRaclip fOR the tReatMent 
Of high-Risk MitRal ReguRgitatiOn
Asgar A.W.1, Khairy P.1, Bernard L.2, Cameron H.L.2, Ducharme A.1, Guertin M.C.1, Bonan R.1, 
L’Allier P.1, Tardif J.C.1, Cohen D.3
1Montreal Heart Institute, Montreal, QC, Canada, 2Cornerstone Research Group, Burlington, ON, 
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Objectives: Mitral regurgitation (MR), a cardiac disease resulting in volume 
overload, is associated with an increased risk of heart failure and mortal-
ity. Standard care for MR is surgical repair or replacement of the mitral valve. 
Patients at high risk for surgical intervention, such as those with functional MR, 
are often relegated to medical management alone. The MitraClip is a transcath-
eter device, which performs percutaneous edge-to-edge repair to treat MR. We, 
evaluated the real-world clinical and cost effectiveness of MitraClip in high-risk 
MR patients. MethOds: Data for patients receiving MitraClip were obtained 
from a prospective registry of high-risk MR patients treated at the Montreal Heart 
Institute (MHI) in Quebec from December 2010 to May 2013. These patients were 
propensity matched on baseline characteristics and medical therapy to medically 
treated MR patients followed at the MHI Heart Failure Clinic from 2008 to 2011. 
Cohorts were compared on clinical and economic outcomes, quality of life (QoL), 
complications/adverse events, emergency room (ER) visits, hospitalizations, 
surgical intervention, and clinic visits. Based on data from this matched com-
parison, we then developed a decision analytic model to assess the incremental 
cost-effectiveness of MitraClip vs. medical therapy in patients with high-risk 
MR. Survival for each group was extrapolated beyond follow-up to 10 years using 
Weibull regression. Unit costs were obtained from the MHI. Costs and benefits 
were discounted at 5% per annum. One-way and probabilistic sensitivity analyses 
were performed. Results: Compared with medical therapy, treatment with Mi-
traClip was associated with a gain of 1.34 quality-adjusted life years (QALYs) and 
an incremental cost of $48,970 (Canadian). The incremental cost-effectiveness 
ratio (ICER) was $36,543 per QALY gained. cOnclusiOns: Based on data from 
our matched, observational comparison, treatment with the MitraClip appears 
to be an economically attractive alternative to medical therapy for high-risk 
patients with MR.
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tion between items while indicating how strongly an item is preferred. This study 
investigated the use of MaxDiff as a means of determining patient-reported impor-
tance of medication treatment attributes. MethOds: MaxDiff was used in a survey 
of rheumatoid arthritis (RA) patients to determine the importance and relative 
rank of specific attributes of RA treatments. The following attributes were selected 
based upon literature review and opinions of the research team: 1) Reduces pain; 2) 
Potential side effects; 3) How often treatment taken; 4) How treatment is given; 5) 
Where treatment is given; 6) Personal costs; 7) Works quickly; 8) How long treatment 
effects last; 9) Keeps disease from getting worse; and 10) Improves physical abilities. 
Respondents were shown 10 sets of 4 attributes and, for each set, were asked to 
indicate the RA treatment attribute that was most important and least important 
to them. The attribute sets were selected using an experimental design that showed 
each attribute an equal number of times and in different order within the sets. 
Hierarchical Bayesian techniques were used to derive respondent-level attribute 
importance scores and, based on the importance scores a relative rank order was 
developed for each attribute. Results: Based on 291 surveys, MaxDiff attribute 
importance scores ranged from 13 to 209 with higher scores indicating increased 
importance. Preventing the disease from getting worse, improving physical abili-
ties, and reduction in pain were the most important RA treatment attributes, all 
having scores > 195, while the ‘how’, ‘when’, and ‘where’ treatment administration 
attributes were the least important, all having scores < 15. cOnclusiOns: MaxDiff 
importance scores demonstrated discrimination among attributes and respondents 
and should be considered as an alternative to more traditional ranking and rating 
approaches.
pp3
hOw canadians value RaRe diseases given theiR OppORtunity cOst?
Rizzardo S., Bansback N., Mitton C., Marra C., Lynd L.
University of British Columbia, Vancouver, BC, Canada
Expensive rare disease treatments pose a problem for decision makers who are 
expected to judiciously allocate health care dollars to maximize benefit. If the 
Canadian public prioritize rare diseases for funding given their opportunity cost, 
this would reveal their value for rare disease treatment. This preference would 
in turn justify devoting limited resources to these conditions. Objectives: 
Determine whether society 1) values the treatment of rare diseases over common 
diseases and, 2) accepts the opportunity costs associated with funding high-cost 
medications. MethOds: In an online survey, 2211 subjects from across Canada 
were presented with 13 scenarios asking them choose between funding a rare dis-
ease, and either a common disease or societal benefit in a simple trade-off design. 
Embedded in the scenarios were factors and values related to rarity. Results: The 
rare disease was favoured by the majority of subjects in only 2 scenarios out of 9 
where the alternate was a common disease, and in 3 scenarios out of 4 where the 
alternate was a societal benefit. Canadians preferred to fund rare disease treat-
ment over education, recreation or smoking cessation programs. Factors which 
resulted in greater than 30% of subjects selecting the rare disease included unmet 
need, disease severity and young age. As treatment costs for the rare disease 
increased, it was increasingly less likely to be funded over the common disease. 
Knowing someone with, or having a rare disease was significantly associated with 
favouring the rare disease in 10 out of 13 scenarios. cOnclusiOns: Canadians 
prefer to use resources to fund treatment of rare diseases over other societal 
benefits including recreation and education; however, they prefer to maximize 
health care resources to benefit the greatest number of people. Rare diseases are 
valued by Canadians only when the opportunity cost to treat them does not take 
away from common disease treatments.
pp4
patient pRefeRences Of tReatMents aMOng wOMen with Metastatic 
BReast canceR: Results fROM a cOnjOint analysis study
DiBonaventura M.1, Copher R.2, Basurto E.1, Faria C.2, Lorenzo R.1
1Kantar Health, New York, NY, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA
Objectives: Although a growing number of treatment options are available for 
metastatic breast cancer (mBC), each treatment is associated with its own various 
advantages and disadvantages. It remains unclear how patients value the differ-
ent treatment characteristics and whether preferences vary as a function of prior 
treatment experience. MethOds: Data were collected through a cross-sectional 
Internet survey of 181 women diagnosed with mBC who had prior experience 
with either a taxane, paclitaxel, or docetaxel. Patients provided demographic, 
health history, and health outcomes information. Participants also completed a 
choice-based conjoint exercise that included a series of choice questions. Each 
choice question included a pair of hypothetical treatments which were presented 
in terms of eight safety attributes (alopecia, motor neuropathy, myalgia/arthralgia, 
nausea/vomiting, fatigue, neutropenia, mucositis/stomatitis, and diarrhea), one 
effectiveness attribute, one dosing regimen attribute, and one quality of life attrib-
ute. Choice task data were analyzed using hierarchical Bayesian logistic regres-
sion models. Relative importances (RI) were reported and provide the magnitude 
of each attribute’s influence on treatment preference on a common ratio scale 
(e.g., an RI of 50% is twice as influential as an RI of 25%). Results: Women had 
a mean age of 52.24 years and 93.92% were non-Hispanic white. Effectiveness 
(RI= 33.49%) was most strongly associated with treatment preference, followed 
by alopecia (RI= 21.32%), fatigue (RI= 12.46%), neutropenia (RI= 10.37%), and qual-
ity of life (RI= 7.69%). Myalgia (RI= 0.48%), mucositis (RI= 0.43%), and dosing regi-
men (RI= 0.14%) had the weakest associations with preference. These preferences 
did not vary as a function of chemotherapy experience. cOnclusiOns: Despite 
the risk of serious adverse events, incremental survival (1-3 months) is influential 
in patient preferences for chemotherapy. Furthermore, quality of life improve-
ments were more influential in treatment preferences than most adverse events. 
These findings help clarify the patient perspective of mBC treatments which, 
if aligned with prescribing patterns, may maximize treatment satisfaction and 
adherence.
37-40 per 1000 for hypertension, 22-26 for heart disease, 15-18 for diabetes, and 6-9 
for cancer, COPD, and stroke. The strongest predictors of disease onset were insur-
ance status, behavioral risk factors, and comorbid conditions. cOnclusiOns:  The 
Population Health Model we developed is a health economic evaluation tool, which 
can predict future health outcomes for a cohort of Massachusetts residents over 
50 based on their individual characteristics. The simulation results were validated 
using selected national datasets (US and Canada). Our next step is to predict health 
care costs over time based on the health status micro-simulation and information 
from both the Medical Expenditure Panel Survey and Massachusetts insurance 
claims data.
MO4
an eMpiRical cOMpaRisOn Of a MaRkOv cOhORt MOdel and a discRete 
event siMulatiOn fOR cOst-effectiveness analysis in ORthOpaedics
Standfield L.B., Comans T., Scuffham P.A.
Griffith University, Meadowbrook, Australia
Objectives: Discrete event simulation (DES) models are becoming more popu-
lar with modellers undertaking cost-effectiveness analyses. However, there is a 
dearth of empirical examples directly comparing DES with Markov cohort models 
(MM). This study applied these methods to a common dataset describing an ortho-
paedic physiotherapy screening clinic and multidisciplinary service (OPSC) versus 
usual orthopaedic care (UOC) to compare the empirical differences between these 
modelling methods and evaluate the cost-effectiveness of OPSC. MethOds:  A 
MM and a DES were constructed using TreeAge Pro and Simul8, respectively. Data 
were obtained from hospital administrative sources and a retrospective chart audit 
of 980 patients with a primary diagnosis involving the knee, shoulder or lumbar 
spine attending an OPSC. Detailed analyses of disaggregated cost and effect esti-
mates generated by each model are performed. Uncertainty in each model is inves-
tigated using probabilistic sensitivity analyses (PSA). Results:  Both economic 
models generated similar costs estimates (MM-UOC= $1287; DES-UOC = $1322; 
MM-OPSC= $1403; DES-OPSC= $1419; MM incremental cost (IC)= $116; DES IC= $97). 
Each model generated comparable quality-adjusted life year saved (QALY) estimates 
(MM-UOC= 2.74; DES-UOC= 2.72; MM-OPSC= 2.81; DES-OPSC= 2.79; MM incremental 
effect (IE)= 0.066; DES IE= 0.068). The incremental cost-effectiveness ratios (ICERs) 
generated by the MM and DES were $1756 and $1418 per QALY, respectively. The 
DES model required a considerably longer time to develop and to run (DES run-
time= 80min; MM run-time= 11.8 seconds). However, the DES provided more explicit 
timing of events. cOnclusiOns:  The MM and DES generated similar ICER esti-
mates, which suggest OPSC is cost-effective when compared to UOC. Empirical 
comparisons using the same data source have highlighted differences in develop-
ment and computational time between the MM and DES. The explicit management 
of time in DES also has the potential to generate different results than described by 
the MM. The limitations of this study are also considered.
patient pRefeRence studies
pp1
pRefeRences fOR pROstate canceR OutcOMes: a cOMpaRisOn Of patient 
and geneRal pOpulatiOn peRspectives
Gries K.S.1, Regier D.A.2, Ramsey S.D.3, Patrick D.L.1
1University of Washington, Seattle, WA, USA, 2BC Cancer Agency, Vancouver, BC, Canada, 3Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA
Objectives: Preference values for prostate cancer specific health states vary greatly 
between studies and are influenced by the method of elicitation and study popula-
tion. Given the strengths, limitations, and potential for biases of both patient and 
societal preference values, understanding the magnitude of difference is pertinent 
for application in cost-effectiveness analysis. The objective of this study was to com-
pare patient preferences with those of the general population for several prostate 
cancer specific health states. MethOds: Health state descriptions were developed 
with attributes that varied across five different health domains pertinent to men 
with prostate cancer: sexual function, urinary function, bowel function, pain, and 
emotional well-being. Men with prostate cancer and a representation of the general 
population (men and women) assigned preferences to 16 health states using a visual 
analog scale and standard gamble methodology. Study subjects also completed the 
Health Utilities Index mark 3 (HUI3) to obtain utility values using a generic prefer-
ence measure. Results: A total of 84 participants were enrolled (n= 43 prostate 
cancer; n= 41 general population) and completed the health state valuations. The 
mean age of the men with prostate cancer was 63.4 years (5.46) and 38.8 years (10.7) 
for the general population group. There was a statistically significant difference in 
HUI3 current health ratings between groups: men with prostate cancer HUI3: 0.74 
(standard error; se= 0.23) vs 0.88 (se= 0.19) for the general population (p= 0.006). The 
mean standard gamble utility values for the prostate cancer health states ranged 
from 0.85 to 0.46 among men with prostate cancer and from 0.81 to 0.32 among the 
non-cancer group. Two-group mean comparison test did not indicate statistical 
significance for the 16 health states (p-value: 0.93 - 0.09). cOnclusiOns: There 
were no statistically significant differences in standard gamble valuations of pros-
tate cancer specific health states when comparing the patient perspective with 
the societal perspective.
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MaxiMuM diffeRence scaling: a nOvel technique fOR deteRMining 
patient pRefeRences
Stephenson J.J.1, Kern D.M.1, Wu B.1, Tunceli O.1, Rodriguez A.1, Horne L.N.2, Sackeyfio A.3, 
Mackillop N.3
1HealthCore, Inc., Wilmington, DE, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 
3AstraZeneca, Alderley Park, UK
Objectives: Maximum Difference Scaling (MaxDiff) is a survey research technique 
for obtaining preference scores for a set of items that provides greater discrimina-
